Switch theme
Sign up to access all valuation multiples
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
2016
112
Last FY Revenue n/a
LTM EBITDA -$194M
$931M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vera Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$194M.
In the most recent fiscal year, Vera Therapeutics achieved revenue of n/a and an EBITDA of -$144M.
Vera Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vera Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$194M | XXX | -$144M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$200M | XXX | -$167M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$186M | XXX | -$152M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Vera Therapeutics's stock price is $23.
Vera Therapeutics has current market cap of $1.5B, and EV of $931M.
See Vera Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $931M | $1.5B | XXX | XXX | XXX | XXX | $-3.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Vera Therapeutics has market cap of $1.5B and EV of $931M.
Vera Therapeutics's trades at n/a EV/Revenue multiple, and -6.4x EV/EBITDA.
Equity research analysts estimate Vera Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vera Therapeutics has a P/E ratio of -7.9x.
See valuation multiples for Vera Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV (current) | $931M | XXX | $931M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -4.8x | XXX | -6.4x | XXX | XXX | XXX |
| EV/EBIT | -4.6x | XXX | -5.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -7.9x | XXX | -9.6x | XXX | XXX | XXX |
| EV/FCF | -5.8x | XXX | -6.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVera Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.5M for the same period.
Vera Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Vera Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Vera Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vera Therapeutics acquired XXX companies to date.
Last acquisition by Vera Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Vera Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Vera Therapeutics founded? | Vera Therapeutics was founded in 2016. |
| Where is Vera Therapeutics headquartered? | Vera Therapeutics is headquartered in United States of America. |
| How many employees does Vera Therapeutics have? | As of today, Vera Therapeutics has 112 employees. |
| Who is the CEO of Vera Therapeutics? | Vera Therapeutics's CEO is Dr. Marshall Fordyce, M.D.. |
| Is Vera Therapeutics publicy listed? | Yes, Vera Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Vera Therapeutics? | Vera Therapeutics trades under VERA ticker. |
| When did Vera Therapeutics go public? | Vera Therapeutics went public in 2021. |
| Who are competitors of Vera Therapeutics? | Similar companies to Vera Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Vera Therapeutics? | Vera Therapeutics's current market cap is $1.5B |
| Is Vera Therapeutics profitable? | Yes, Vera Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Vera Therapeutics? | Vera Therapeutics's last 12 months EBITDA is -$194M. |
| What is the current EV/EBITDA multiple of Vera Therapeutics? | Current EBITDA multiple of Vera Therapeutics is -4.8x. |
| What is the current FCF of Vera Therapeutics? | Vera Therapeutics's last 12 months FCF is -$159M. |
| What is the current EV/FCF multiple of Vera Therapeutics? | Current FCF multiple of Vera Therapeutics is -5.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
